F. Tas et al., Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer, J EXP CL C, 19(4), 2000, pp. 477-481
Citations number
29
Categorie Soggetti
Oncology
Journal title
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
The aim of this study is to assess the clinical usefulness of serum assays
of carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), a
nd CYFRA 21.1 in the diagnosis of squamous cell lung cancer. Sixty patients
with squamous cell, and twenty-four patients with nonsquamous cell histolo
gy of nonsmall cell lung cancer were enrolled in this study. Serum CEA, SCC
, and CYFRA 21.1 levels were obtained by commercially available kits. Upper
cutoff levels were 10 ng/ml, 3.5 ng/ml, and 3.5 ng/ml, respectively. In sq
uamous cell lung cancer, percentages and 95% confidence interval (CI) of th
e patients with elevated levels were as follows: for CEA 23.3% (13-36), for
SCC 20.0% (10-32), and for CYFRA 21.1 85.0% (73-93). The positivity rate o
f CYFRA 21.1 was more significant than CEA and SCC in both squamous and non
squamous cell lung cancer. None of the markers were significant in differen
tiating squamous/nonsquamous histology. Only tumor marker CEA was significa
ntly elevated in metastatic squamous cell lung cancer (p=0.004). A novel tu
mor marker CYFRA 21.1 can be used as a reliable tumor marker in diagnosing
squamous cell lung cancer. In addition, CEA has an important role in determ
ining metastatic disease.